144036-17-9

Basic information

• Product Name: 3-(CYCLOPENTYLOXY)-4-METHOXYBENZOIC ACID
• Synonyms: 3-(CYCLOPENTYLOXY)-4-METHOXYBENZOIC ACID;BUTTPARK 75\04-33;RARECHEM AL BO 1947;3-(Cyclopentyloxy)-4-methoxybezoic acid
• CAS NO: 144036-17-9
• Molecular Formula: C₁₃H₁₆O₄
• Molecular Weight: 236.26
• Product Categories: Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts
• Mol File: 144036-17-9.mol
• Article Data: 13

Chemical Properties

• Melting Point: 160-164°C
• Boiling Point: 376.3°Cat760mmHg
• Flash Point: 142°C
• Appearance: /
• Density: 1.213±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 2.48E-06mmHg at 25°C
• Refractive Index: 1.559
• Storage Temp.: 2-8°C
• PKA: 4.22±0.10(Predicted)
• CAS DataBase Reference: 3-(CYCLOPENTYLOXY)-4-METHOXYBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(CYCLOPENTYLOXY)-4-METHOXYBENZOIC ACID(144036-17-9)
• EPA Substance Registry System: 3-(CYCLOPENTYLOXY)-4-METHOXYBENZOIC ACID(144036-17-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-36
• Safety Statements: 26-36/37/39
• WGK Germany: 3
• Hazardous Substances Data: 144036-17-9(Hazardous Substances Data)

Usage

General Description

3-(Cyclopentyloxy)-4-methoxybenzoic acid is a chemical compound that belongs to the class of carboxylic acid derivatives. It is a white crystalline powder with a molecular formula of C13H14O4 and a molecular weight of 234.25 g/mol. 3-(CYCLOPENTYLOXY)-4-METHOXYBENZOIC ACID is used in various industrial processes and research applications, including as a building block in the synthesis of pharmaceuticals and agrochemicals. Its properties and structure make it suitable for use in the production of dyes, pigments, and other functional materials. Additionally, 3-(Cyclopentyloxy)-4-methoxybenzoic acid has potential uses in medical and biological research, particularly in the development of new drugs and therapeutic agents.

InChI:InChI=1/C13H16O4/c1-16-11-7-6-9(13(14)15)8-12(11)17-10-4-2-3-5-10/h6-8,10H,2-5H2,1H3,(H,14,15)

Upstream product

• 154464-24-1 methyl 3-(cyclopentyloxy)-4-methoxybenzoate 
• 6702-50-7 3-hydroxy-4-methoxybenzoate 
• 621-59-0 isovanillin 
• 5329-14-6 aminosulfonic acid 
• 67387-76-2 3-cyclopentyloxy-4-methoxybenzylaldehyde 
• 7758-19-2 sodium chlorite 
• 137-43-9 Cyclopentyl bromide 

Downstream Products

• 144036-19-1 3-cyclopentyloxy-4-methoxy benzoic acid chloride 
• 159783-15-0 N-methoxy-N-methyl-3-cyclopentoxy-4-methoxybenzamide 
• 141184-48-7 1-[3-(cyclopentyloxy)-4-methoxyphenyl]-ethanone 
• 158429-29-9 2-N[3-(cyclopentyloxy)-4-methoxyphenylcarbonyl]amino-3-hydroxypyridine 
• 158429-30-2 3-cyclopentyloxy-4-methoxybenzthioamide 

Relevant articles and documents

Comparison of the full-length and 152~528 truncate of human cyclic nucleotide phosphodiesterase 4b2 for the characterization of inhibitors

Aim and Objective: Human full-length cyclic nucleotide phosphodiesterase isozyme 4B2 (hPDE4B2) as the target for screening and characterizing inhibitors suffers from low activity yield and the coexistence of two conformational states bearing different aff

Synthesis, biological evaluation, and molecular modeling of new 3-(cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2- oxoethyl) oxime (GEBR-7b) related phosphodiesterase 4D (PDE4D) inhibitors

A new series of 3-(cyclopentyloxy)-4-methoxyphenyl derivatives, structurally related to our hit GEBR-4a (1) and GEBR-7b (2), has been designed by changing length and functionality of the chain linking the catecholic moiety to the terminal cycloamine portion. Among the numerous molecules synthesized, compounds 8, 10a, and 10b showed increased potency as PDE4D enzyme inhibitors with respect to 2 and a good selectivity against PDE4A4, PDE4B2, and PDE4C2 enzymes, without both cytotoxic and genotoxic effects. The ability to enhance cAMP level in neuronal cells was assessed for compound 8. SAR considerations, also confirmed by in silico docking simulations, evidenced that both chain and amino terminal function characterized by higher hydrophilicity are required for a good and selective inhibitor-catalytic pocket interaction.

INHIBITORS OF PHOSPHODIESTERASE TYPE-IV

The present invention relates to oxazine derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. Compounds disclosed herein can be useful in the treatment of CMS disorders, AIDS, asthma, arthritis, bronchitis, chronic ob